Roche
Roche achieved solid sales growth in the first three quarters of 2025. This result was driven by strong demand for novel medicines and diagnostics, as well as a robust pipeline. The company is raising its profit forecast and showing progress with numerous new drugs for the treatment of serious diseases such as Alzheimer's, hemophilia, cancer, and obesity.
Roche plans to invest $50 billion in the US over the next five years. These investments will strengthen the pharmaceutical company's presence in the United States, where it has 13 manufacturing sites and 15 research and development sites for pharmaceuticals and diagnostics. More than 12,000 new jobs are expected to be created, including nearly 6,500 in construction and 1,000 in new and expanded...
Due to the strong demand for new medicines and diagnostics, Roche increased its sales by three percent to CHF 60.5 billion in 2014. In the previous year, sales amounted to CHF 58.7 billion. Adjusted for currency effects, sales even rose by seven percent. Core operating profit rose by eight percent as a result of higher sales, an improved gross profit margin and efficient cost management. CEO...
Roche plans to acquire the biopharmaceutical company Poseida Therapeutics to expand its offering in the fields of oncology, immunology and neurology. The Basel-based pharmaceutical company is investing around $1 billion, or approximately €950 million, in the acquisition. The transaction is expected to be completed in the first quarter of 2025. Poseida Therapeutics specializes in CAR-T cell...
Roche increased its sales by two percent to almost CHF 45 billion in the first nine months of 2024. Adjusted for currency effects, the pharmaceutical company achieved sales growth of six percent from January to September. Strong demand for modern medicines and diagnostics more than offset the expected decline in Covid-19 sales and the effects of erosion by biosimilars/generics. These include...
Roche has opened the new pharmaceutical research and development center “pRED” at its headquarters in Basel. Equipped with cutting-edge technology and around 1,800 state-of-the-art laboratory and office workstations, the new center brings together researchers from different disciplines to advance scientific discoveries for patients. With this state-of-the-art research and development center, the...
A strong Swiss franc as well as the decline in sales in the coronavirus business and strong competition from generic products have impacted Roche in 2023. In the past financial year, the pharmaceutical company recorded sales growth of one percent at constant exchange rates to CHF 58.7 billion. This increase in sales compensated for the expected decline in Covid-19 sales of over CHF 4 billion and...
Even though Roche's pharmaceuticals business with prescription medicines continues to grow, the company suffered declining overall sales in the first half of 2023 due to the expected drop in demand for Covid-19 products. Roche Group sales fell eight percent to CHF 29.8 billion. The appreciation of the Swiss franc against most currencies had an additional negative impact on the results presented in...
Shrinking demand for tests and medicines to treat Covid-19 has left its mark on Roche's annual results. The bottom line saw net income fall six percent to 13.5 billion Swiss francs from 14.9 billion a year earlier. The Swiss pharmaceutical group posted sales of 63.3 billion Swiss francs in 2022. This represents an increase of two percent. The Pharmaceuticals Division contributed the largest share...
Roche announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX). The Roche nanopore sequencer, once developed, will utilise a novel approach that combines electronic and biological components to...
